Colorectal and Pancreatic Cancer - AV-380-22-102

Summary: This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT05865535?id=AV-380&rank=1

Locations: Hartford Hospital, Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut

Contact: Hayley Dunnack: Hayley.Dunnack@hhchealth.org